Self-powered flexible skin patch using bendable microneedles for transdermal insulin delivery is developed. In addition, a drug delivery volume sensor and fluidic control system (validated by in vivo experiments in rats) are also integrated within the patch. This allows users to control or modulate the delivery volume whenever necessary.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
FIGURES OF MERIT
Value Proposition: In an article published in PubMed Central, global diabetes market yielded $28.1 billion in sales, with 58% of that generated in the U.S in 2012. Based on prediction, global sales are growing at CAGR of 9.2% to $67.7 billion in 2022, with $38.8 billion in the U.S.
Biopharmaceutical companies are developing therapeutic products to reduce complications, and improve clinical outcomes and quality of life for people with diabetes such as transdermal delivery patch.
These conventional skin patches are typically continuous release patch or gel type that release smaller dose. However, they may not be able to monitor or modulate the dose delivery or they still require conventional insulin therapy through needle injection. These in turn, increases the risk of complication and cost of ownership.
As such, it is anticipated that there is a need to develop skin patch that is able to monitor and control the dosage delivery.
Recently, we developed a toward self-powered skin patch that has high dosage controllability. Potential applications such as wearable drug therapy for chronic disease patients where well controlled dose is needed.
This technology has the ability to load and sense the drug volume that is not available in existing skin patches.
Organization Type: Academic/Gov Lab
Showcase Booth #: 528
GOVT/EXTERNAL FUNDING SOURCES